Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer

Ming Chuan Wang, Ying Hua Chang, Chih Chieh Wu, Yu Chang Tyan, Hua Chien Chang, Yih Gang Goan, Wu Wei Lai, Pin Nan Cheng, Pao Chi Liao

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND:: Differential expression and secretion of alpha-actinin 4 (ACTN4) in the lung cancer cell lines CL1-0 and CL1-5 have been reported in previous proteomic studies. The aim of this study is to investigate the functional properties of the ACTN4 protein in non-small-cell lung cancer (NSCLC) cells and evaluate its clinical importance. METHODS:: We used RNA interference to knock down and overexpress ACTN4 protein to evaluate the effects of this intervention on cancer cell invasion and migration, as well as on microscopic cellular morphology. Furthermore, we examined by immunohistochemistry the expression of ACTN4 protein in tissue samples at different stages of lung cancerand compared the protein levels of ACTN4 in blood plasma samples from patients with histologically confirmed lung cancer and healthy controls. RESULTS:: CL1-5 cell motility was significantly suppressed by the knockdown of ACTN4 protein. The morphology of CL1-5 cells changed from a predominantly mesenchymal-like shape into a globular shape in response to ACTN4 protein knockdown. A quantitative immunohistochemical assessment of lung cancer tissues revealed that ACTN4 protein level was considerably higher in cancerous tissues than in the adjacent normal ones, and the area under the receiver operating characteristic curve was 0.736 (p < 0.001). According to an enzyme-linked immunosorbent assay, the plasma levels of ACTN4 protein were significantly different between cancer patients and healthy controls, and the areas under the receiver operating characteristic curves were 0.828 and 0.909, respectively, for two independent cohorts (p < 0.001). CONCLUSIONS:: We demonstrate that the knockdown of ACTN4 protein inhibited cell invasion and migration. These results suggest that ACTN4 is associated with lung cancer cell motility. Thus, the level of ACTN4 in cancerous tissue and plasma is related to the presence of lung cancer.

Original languageEnglish
Pages (from-to)286-301
Number of pages16
JournalJournal of Thoracic Oncology
Volume10
Issue number2
DOIs
Publication statusPublished - 2015 Feb 6

Fingerprint

Actinin
Non-Small Cell Lung Carcinoma
Cell Movement
Biomarkers
Neoplasms
Lung Neoplasms
Proteins
ROC Curve
RNA Interference
Proteomics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

@article{c1319d83911146be9c3cbeac722279d5,
title = "Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer",
abstract = "BACKGROUND:: Differential expression and secretion of alpha-actinin 4 (ACTN4) in the lung cancer cell lines CL1-0 and CL1-5 have been reported in previous proteomic studies. The aim of this study is to investigate the functional properties of the ACTN4 protein in non-small-cell lung cancer (NSCLC) cells and evaluate its clinical importance. METHODS:: We used RNA interference to knock down and overexpress ACTN4 protein to evaluate the effects of this intervention on cancer cell invasion and migration, as well as on microscopic cellular morphology. Furthermore, we examined by immunohistochemistry the expression of ACTN4 protein in tissue samples at different stages of lung cancerand compared the protein levels of ACTN4 in blood plasma samples from patients with histologically confirmed lung cancer and healthy controls. RESULTS:: CL1-5 cell motility was significantly suppressed by the knockdown of ACTN4 protein. The morphology of CL1-5 cells changed from a predominantly mesenchymal-like shape into a globular shape in response to ACTN4 protein knockdown. A quantitative immunohistochemical assessment of lung cancer tissues revealed that ACTN4 protein level was considerably higher in cancerous tissues than in the adjacent normal ones, and the area under the receiver operating characteristic curve was 0.736 (p < 0.001). According to an enzyme-linked immunosorbent assay, the plasma levels of ACTN4 protein were significantly different between cancer patients and healthy controls, and the areas under the receiver operating characteristic curves were 0.828 and 0.909, respectively, for two independent cohorts (p < 0.001). CONCLUSIONS:: We demonstrate that the knockdown of ACTN4 protein inhibited cell invasion and migration. These results suggest that ACTN4 is associated with lung cancer cell motility. Thus, the level of ACTN4 in cancerous tissue and plasma is related to the presence of lung cancer.",
author = "Wang, {Ming Chuan} and Chang, {Ying Hua} and Wu, {Chih Chieh} and Tyan, {Yu Chang} and Chang, {Hua Chien} and Goan, {Yih Gang} and Lai, {Wu Wei} and Cheng, {Pin Nan} and Liao, {Pao Chi}",
year = "2015",
month = "2",
day = "6",
doi = "10.1097/JTO.0000000000000396",
language = "English",
volume = "10",
pages = "286--301",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "2",

}

Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer. / Wang, Ming Chuan; Chang, Ying Hua; Wu, Chih Chieh; Tyan, Yu Chang; Chang, Hua Chien; Goan, Yih Gang; Lai, Wu Wei; Cheng, Pin Nan; Liao, Pao Chi.

In: Journal of Thoracic Oncology, Vol. 10, No. 2, 06.02.2015, p. 286-301.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer

AU - Wang, Ming Chuan

AU - Chang, Ying Hua

AU - Wu, Chih Chieh

AU - Tyan, Yu Chang

AU - Chang, Hua Chien

AU - Goan, Yih Gang

AU - Lai, Wu Wei

AU - Cheng, Pin Nan

AU - Liao, Pao Chi

PY - 2015/2/6

Y1 - 2015/2/6

N2 - BACKGROUND:: Differential expression and secretion of alpha-actinin 4 (ACTN4) in the lung cancer cell lines CL1-0 and CL1-5 have been reported in previous proteomic studies. The aim of this study is to investigate the functional properties of the ACTN4 protein in non-small-cell lung cancer (NSCLC) cells and evaluate its clinical importance. METHODS:: We used RNA interference to knock down and overexpress ACTN4 protein to evaluate the effects of this intervention on cancer cell invasion and migration, as well as on microscopic cellular morphology. Furthermore, we examined by immunohistochemistry the expression of ACTN4 protein in tissue samples at different stages of lung cancerand compared the protein levels of ACTN4 in blood plasma samples from patients with histologically confirmed lung cancer and healthy controls. RESULTS:: CL1-5 cell motility was significantly suppressed by the knockdown of ACTN4 protein. The morphology of CL1-5 cells changed from a predominantly mesenchymal-like shape into a globular shape in response to ACTN4 protein knockdown. A quantitative immunohistochemical assessment of lung cancer tissues revealed that ACTN4 protein level was considerably higher in cancerous tissues than in the adjacent normal ones, and the area under the receiver operating characteristic curve was 0.736 (p < 0.001). According to an enzyme-linked immunosorbent assay, the plasma levels of ACTN4 protein were significantly different between cancer patients and healthy controls, and the areas under the receiver operating characteristic curves were 0.828 and 0.909, respectively, for two independent cohorts (p < 0.001). CONCLUSIONS:: We demonstrate that the knockdown of ACTN4 protein inhibited cell invasion and migration. These results suggest that ACTN4 is associated with lung cancer cell motility. Thus, the level of ACTN4 in cancerous tissue and plasma is related to the presence of lung cancer.

AB - BACKGROUND:: Differential expression and secretion of alpha-actinin 4 (ACTN4) in the lung cancer cell lines CL1-0 and CL1-5 have been reported in previous proteomic studies. The aim of this study is to investigate the functional properties of the ACTN4 protein in non-small-cell lung cancer (NSCLC) cells and evaluate its clinical importance. METHODS:: We used RNA interference to knock down and overexpress ACTN4 protein to evaluate the effects of this intervention on cancer cell invasion and migration, as well as on microscopic cellular morphology. Furthermore, we examined by immunohistochemistry the expression of ACTN4 protein in tissue samples at different stages of lung cancerand compared the protein levels of ACTN4 in blood plasma samples from patients with histologically confirmed lung cancer and healthy controls. RESULTS:: CL1-5 cell motility was significantly suppressed by the knockdown of ACTN4 protein. The morphology of CL1-5 cells changed from a predominantly mesenchymal-like shape into a globular shape in response to ACTN4 protein knockdown. A quantitative immunohistochemical assessment of lung cancer tissues revealed that ACTN4 protein level was considerably higher in cancerous tissues than in the adjacent normal ones, and the area under the receiver operating characteristic curve was 0.736 (p < 0.001). According to an enzyme-linked immunosorbent assay, the plasma levels of ACTN4 protein were significantly different between cancer patients and healthy controls, and the areas under the receiver operating characteristic curves were 0.828 and 0.909, respectively, for two independent cohorts (p < 0.001). CONCLUSIONS:: We demonstrate that the knockdown of ACTN4 protein inhibited cell invasion and migration. These results suggest that ACTN4 is associated with lung cancer cell motility. Thus, the level of ACTN4 in cancerous tissue and plasma is related to the presence of lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=84922247991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922247991&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000396

DO - 10.1097/JTO.0000000000000396

M3 - Article

C2 - 25299231

AN - SCOPUS:84922247991

VL - 10

SP - 286

EP - 301

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 2

ER -